HIV drug resistance mutations in proviral DNA from a community treatment program

PLoS ONE

Volumn 10, Issue 1, 2015, Pages

  Derache, Anne ^a   Shin, Hyoung Shik ^b   Balamane, Maya ^a   White, Elizabeth ^a   Israelski, Dennis ^a   Klausner, Jeffrey D ^c   Freeman, Alexandra H ^d   Katzenstein, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Asian Pac Res Found Infect Dis   (South Korea)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; DNA; EFAVIRENZ; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROVIRAL DNA; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; STRUCTURAL GENE; VIREMIA; VIRUS LOAD; DEMOGRAPHY; FOLLOW UP; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PROVIRUS; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEMOGRAPHY; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; PHYLOGENY; PROVIRUSES; RESIDENCE CHARACTERISTICS; VIREMIA;

EID: 84922438049     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117430     Document Type: Article

References (71)

1. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS (1998) Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med Jul 6; 188(1):83-91. Erratum in: J Exp Med 1998 Aug 3;188(3):following 614. PMID: 9653086
2. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science Nov 14; 278(5341):1295-300. PMID: 9360927
3. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, et al. (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med Jun; 9(6):727-8. PMID: 12754504
4. Chew CB, Potter SJ, Wang B, Wang YM, Shaw CO, et al. (2005) Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol Jul; 33(3):206-16. PMID: 15911442
5. Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T, et al. (2009) Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis Feb 15; 48(4):462-72. doi: 10.1086/596486 PMID: 19133804
6. MacLeod IJ, Rowley CF, Thior I, Wester C, Makhema J, et al. (2010) Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART. J Clin Virol Jul; 48 (3):162-7. doi: 10.1016/j.jcv.2010.03.017 PMID: 20427228
7. Neogi U, Shet A, Sahoo PN, Bontell I, Ekstrand ML, et al. (2013) Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals. J Int AIDS Soc Feb 25; 16:18472. doi: 10.7448/IAS.16.1.18472 PMID: 23443042
8. Bi X, Gatanaga H, Ida S, Tsuchiya K, Matsuoka-Aizawa S, et al. (2003) Emergence of protease inhibitor resistance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year. J Acquir Immune Defic Syndr Sep 1; 34(1):1-6. PMID: 14501787
9. Lambotte O, Chaix ML, Gubler B, Nasreddine N, Wallon C, et al. (2004) The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS May 21; 18(8):1147-58. PMID: 15166530
10. Verhofstede C, Wanzeele FV, Van Der Gucht B, De Cabooter N, Plum J (1999) Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS Dec 24; 13(18):2541-6. PMID: 10630523
11. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, et al. (1999) Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet Aug 28; 354(9180):729-33. PMID: 10475184
12. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, et al. (2001) Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med Feb 15; 344(7):472-80. PMID: 11172188
13. Devereux HL, Loveday C, Youle M, Sabin CA, Burke A, et al. (2000) Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients. AIDS Res Hum Retroviruses Jul 20; 16(11):1025-30. PMID: 10933616
14. Verhofstede C, Noë A, Demecheleer E, De Cabooter N, Van Wanzeele F, et al. (2004) Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy. J Acquir Immune Defic Syndr Apr 15; 35(5):473-83. PMID: 15021312
15. Falasca F, Montagna C, Maida P, Bucci M, Fantauzzi A, et al. (2013) Analysis of intracellular human immunodeficiency virus (HIV)-1 drug resistance mutations in multi-failed HIV-1-infected patients treated with a salvage regimen: 72-week follow-up. Clin Microbiol Infect Jul; 19(7):E318-21. doi: 10.1111/1469-0691.12175 PMID: 23438096
16. Noë A, Plum J, Verhofstede C (2005) The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance. J Antimicrob Chemother Apr; 55(4):410-2. PMID: 15728140
17. Turriziani O, Andreoni M, Antonelli G (2010) Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection. Clin Microbiol Infect Oct; 16(10):1518-24. doi: 10.1111/j.1469-0691.2010.03329.x PMID: 20673260
18. Mohamed S, Ravet S, Camus C, Khiri H, Olive D, et al. (2014) Clinical and analytical relevance of NNRTIs minority mutations on viral failure in HIV-1 infected patients. J Med Virol Mar; 86(3):394-403. doi: 10.1002/jmv.23853 PMID: 24248806
19. Rowley CF, Boutwell CL, Lee EJ, MacLeod IJ, Ribaudo HJ, et al. (2010) Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance. AIDS Res Hum Retroviruses Mar; 26(3):293-300. doi: 10.1089/aid.2009.0082 PMID: 20334564
20. Stekler JD, Ellis GM, Carlsson J, Eilers B, Holte S, et al. (2011) Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection. PLoS One 6(12):e28952. doi: 10.1371/journal.pone.0028952 PMID: 22194957
21. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, et al. (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A Nov 25; 94(24):13193-7. PMID: 9371822
22. Nottet HS, van Dijk SJ, Fanoy EB, Goedegebuure IW, de Jong D, et al. (2009) HIV-1 can persist in aged memory CD4+ T lymphocytes with minimal signs of evolution after 8.3 years of effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr Apr 1; 50(4):345-53. doi: 10.1097/QAI.0b013e318197eb04 PMID: 19214126
23. Palmisano L, Giuliano M, Galluzzo CM, Amici R, Andreotti M, et al. (2009) The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy. HIV Med Sep; 10(8):477-81. doi: 10.1111/j.1468-1293.2009.00715.x PMID: 19459989
24. Delaugerre C, Charreau I, Braun J, Néré ML, de Castro N, et al. ANRS 138 study group (2010) Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen. AIDS Sep 24; 24(15):2391-5. doi: 10.1097/QAD.0b013e32833d214c PMID: 20683319
25. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, et al. AIDS Clinical Trials Group A5244 team (2010) The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med Aug 10; 7(8). doi: 10.1371/journal.pmed.1000334 PMID: 20824177
26. McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, et al. (2010) Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis Mar 15; 50(6):912-9. doi: 10.1086/650749 PMID: 20156060
27. Banks L, Gholamin S, White E, Zijenah L, Katzenstein DA (2012) Comparing Peripheral Blood Mononuclear Cell DNA and Circulating Plasma viral RNA pol Genotypes of Subtype C HIV-1. J AIDS Clin Res Feb; 3(2):141-147. PMID: 23019537
28. Geretti AM, Conibear T, Hill A, Johnson JA, Tambuyzer L, et al. SENSE Study Group (2014) Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz. J Antimicrob Chemother Apr; 69(4):1090-7. doi: 10.1093/jac/dkt474 PMID: 24284781
29. Diallo K, Murillo WE, de Rivera IL, Albert J, Zhou Z, et al. (2012) Comparison of HIV-1 resistance profiles in plasma RNA versus PBMC DNA in heavily treated patients in Honduras, a resource-limited country. Int J Mol Epidemiol Genet 3(1):56-65. PMID: 22493752
30. Imaz A, Olmo M, Peñaranda M, Gutiérrez F, Romeu J, et al. STOPAR study team (2013) Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function. Antivir Ther 18(1):125-30. doi: 10.3851/IMP2249 PMID: 22805174
31. Delaugerre C, Braun J, Charreau I, Delarue S, Nere ML, et al. ANRS 138-EASIER study group (2012) Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication. HIV Med Oct; 13(9):517-25. doi: 10.1111/j.1468-1293.2012.01002.x PMID: 22416781
32. Wirden M, Soulie C, Valantin MA, Fourati S, Simon A, et al. (2011) Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. J Antimicrob Chemother Apr; 66(4):709-12. doi: 10.1093/jac/dkq544 PMID: 21393164
33. Bon I, Gibellini D, Borderi M, Alessandrini F, Vitone F, et al. (2007) Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. J Clin Virol Apr; 38(4):313-20. PMID: 17306618
34. Kabamba-Mukadi B, Duquenne A, Henrivaux P, Musuamba F, Ruelle J, et al. (2010) HIV-1 proviral resistance mutations: usefulness in clinical practice. HIV Med Sep; 11(8):483-92. doi: 10.1111/j.1468-1293.2009.00814.x PMID: 20163482
35. Geneious. http://www.geneious.com/.
36. Stanford University HIV Drug Resistance Database. http://hivdb.stanford.edu.
37. Felsenstein J (2008) PHYLIP Phylogeny Inference Package version 3.6. Department of Genome Sciences University of Washington, Seattle. doi: 10.14219/jada.archive.2008.0268 PMID: 25556087
38. Vlad IM, Srinivasan BV, Raykar VC, Duraiswami R, Davis LS (2008) Automatic online tuning for fast Gaussian summation. Advances in Neural Information Processing Systems.
39. Database SUHDR Calibrated Population Resistance tool. http://cpr.stanford.edu/cpr.cgi.
40. Bowser BP, Worl CO, Fulliove RE, Fullilove MT (2014) Post-Script to the Crack Epidemic and Its Link to HIV. Journal of Equity in Health Vol. 3, No 1, 45-54.
41. Bon I, Alessandrini F, Borderi M, Gorini R, Re MC (2007) Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical management. New Microbiol Jul; 30(3):313-7. PMID: 17802917
42. Günthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, et al. (1998) Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol Mar; 72(3):2422-8. PMID: 9499103
43. Monno L, Punzi G, Scarabaggio T, Saracino A, Brindicci G, et al. (2003) Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART. J Med Virol May; 70(1):1-9. PMID: 12629636
44. Murillo W, de Rivera IL, Parham L, Jovel E, Palou E, et al. (2010) Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment. HIV Med Feb; 11(2):95-103. doi: 10.1111/j.1468-1293.2009.00747.x PMID: 19686436
45. Soto-Ramirez LE, Rodriguez-Diaz R, Durán AS, Losso MH, Salomón H, et al. NISDI Perinatal Study Group (2008) Antiretroviral resistance among HIV type 1-infected women first exposed to antiretrovirals during pregnancy: plasma versus PBMCs. AIDS Res Hum Retroviruses Jun; 24(6):797-804. doi: 10.1089/aid.2007.0246 PMID: 18507526
46. Prakash R (2009) DNA structure is more stable than RNA structure. http://www.brighthub.com/science/genetics/articles/16332.aspx.
47. Hassan AS, Nabwera HM, Mwaringa SM, Obonyo CA, Sanders EJ, et al. (2014) HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study. AIDS Res Ther Jan 23; 11(1):9. doi: 10.1186/1742-6405-11-9 PMID: 24456757
48. Pillay S, Bland RM, Lessells RJ, Manasa J, de Oliveira T, et al. (2014) Drug resistance in children at virological failure in a rural KwaZulu-Natal, South Africa, cohort. AIDS Res Ther Jan 20; 11(1):3. doi: 10.1186/1742-6405-11-3 PMID: 24444369
49. Trotter AB, Hong SY, Srikantiah P, Abeyewickreme I, Bertagnolio S, et al. (2013) Systematic review of HIV drug resistance in Southeast Asia. AIDS Rev Jul-Sep; 15(3):162-70. PMID: 24002200
50. Delaugerre C, Chaix ML, Blanche S, Warszawski J, Cornet D, et al. ANRS French Perinatal Cohort (2009) Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. Retrovirology Sep 19; 6:85. doi: 10.1186/1742-4690-6-85 PMID: 19765313
51. Josefsson L, von Stockenstrom S, Faria NR, Sinclair E, Bacchetti P, et al. (2013) The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc Natl Acad Sci U S A Dec 17; 110(51):E4987-96. doi: 10.1073/pnas.1308313110 PMID: 24277811
52. Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, et al. (2010) Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS One Dec 10; 5(12):e15510. doi: 10.1371/journal.pone.0015510 PMID: 21170322
53. Cambiano V, Bertagnolio S, Jordan MR, Lundgren JD, Phillips A (2013) Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings. J Infect Dis Jun 15; 207 Suppl 2:S57-62. doi: 10.1093/infdis/jit111 PMID: 23687290
54. Imade GE, Sagay AS, Chaplin B, Chebu P, Musa J, et al. (2014) Short Communication: Transmitted HIV Drug Resistance in Antiretroviral-Naive Pregnant Women in North Central Nigeria. AIDS Res Hum Retroviruses Feb; 30(2):127-33. doi: 10.1089/AID.2013.0074 PMID: 24164431
55. Kleyn TJ, Liedtke MD, Harrison DL, Lockhart SM, Salvaggio MR, et al. (2014) Incidence of Transmitted Antiretroviral Drug Resistance in Treatment-Naive HIV-1-Infected Persons in a Large South Central United States Clinic. Ann Pharmacother Jan 28.
56. Lai CC, Hung CC, Chen MY, Sun HY, Lu CL, et al. (2012) Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan. J Antimicrob Chemother May; 67(5):1254-60. doi: 10.1093/jac/dkr601 PMID: 22302562
57. Kantor R, Bettendorf D, Bosch RJ, Mann M, Katzenstein D, et al. ACTG A5077 Study Team (2014) HIV-1 RNA Levels and Antiretroviral Drug Resistance in Blood and Non-Blood Compartments from HIV-1-Infected Men and Women enrolled in AIDS Clinical Trials Group Study A5077. PLoS One Apr 3; 9(4):e93537. doi: 10.1371/journal.pone.0093537 PMID: 24699474
58. Greub G, Cozzi-Lepri A, Ledergerber B, Staszewski S, Perrin L, et al. Frankfurt HIV Clinic Cohort and the Swiss HIV Cohort Study (2002) Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS Sep 27; 16(14):1967-9. PMID: 12351960
59. Macias J, Palomares JC, Mira JA, Torres MJ, García-García JA, et al. (2005) Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect Oct; 51(3):195-200. PMID: 16230215
60. Martinez V, Marcelin AG, Morini JP, Deleuze J, Krivine A, et al. (2005) HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS Jul 1; 19 (10):1065-9.
61. Tobin NH, Learn GH, Holte SE, Wang Y, Melvin AJ, et al. (2005) Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol Aug; 79(15):9625-34. PMID: 16014925
62. Africa NDoHS (2010) Clinical guidelines for the management of HIV & AIDS in adults and adolescents. http://www.who.int/hiv/pub/guidelines/south-africa-art.pdf?ua=1.
63. Organization WH (March 2014 Supplement) To the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventinh HIV infection. http://apps.who.int/iris/bitstream/10665/104264/1/9789241506830-eng.pdf?ua=1.
64. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, et al. (2005) G->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol Feb; 79(3):1975-80. PMID: 15650227
65. Fourati S, Malet I, Lambert S, Soulie C, Wirden M, et al. (2012) E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure. AIDS Aug 24; 26(13):1619-24. doi: 10.1097/QAD.0b013e3283560703 PMID: 22695298
66. Pace C, Keller J, Nolan D, James I, Gaudieri S, et al. (2006) Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol Sep; 80(18):9259-69. PMID: 16940537
67. Kim EY, Bhattacharya T, Kunstman K, Swantek P, Koning FA, et al. (2010) Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J Virol Oct; 84(19):10402-5. doi: 10.1128/JVI.01223-10 PMID: 20660203
68. Mulder LC, Harari A, Simon V (2008) Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci U S A Apr 8; 105(14):5501-6. doi: 10.1073/pnas.0710190105 PMID: 18391217
69. Fourati S, Lambert-Niclot S, Soulie C, Malet I, Valantin MA, et al. (2012) HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs. J Antimicrob Chemother Oct; 67(10):2323-6. doi: 10.1093/jac/dks219 PMID: 22687892
70. Quan Y, Xu H, Wainberg MA (2014) Defective HIV-1 quasispecies in the form of multiply drug-resistant proviral DNA within cells can be rescued by superinfection with different subtype variants of HIV-1 and by HIV-2 and SIV. J Antimicrob Chemother Jan; 69(1):21-7. doi: 10.1093/jac/dkt326 PMID: 23963235
71. Watters JK (1994) Trends in risk behavior and HIV seroprevalence in heterosexual injection drug users in San Francisco, 1986-1992. J Acquir Immune Defic Syndr Dec; 7(12):1276-81. PMID: 7965639